Discover
ELVN
Enliven Therapeutics, Inc.
40.98
2 x 28.80
2 x 50.62
bid
ask
+
0.35
0.86%
2 @ 04:00 PM
40.98 +0.00 (0.00%)
| Ytd | 166.10% | |
| 1y | 92.48% |
40.29
day range
41.97
15.14
52 week range
61.15
| Open | 41.00 | Prev Close | 40.63 | Low | 40.29 | High | 41.97 | Mkt Cap | 3.00B |
| Vol | 1.00M | Avg Vol | 1.13M | EPS | -1.67 | P/E | N/A | Forward P/E | -17.41 |
| Beta | 0.34 | Short Ratio | 9.80 | Inst. Own | 114.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 54.25 | 200-d Avg | 40.93 | 1yr Est | 73.67 |
| Income Statement | |||
| Operating Expenses | 37.21M | ||
| Research and Development Expense | 29.00M | ||
| Selling, General and Administrative Expense | 8.21M | ||
| Operating Income | -37.21M | ||
| Net Income | -32.48M | ||
| Net Income Common Stock | -32.48M | ||
| Net Income Common Stock (USD) | -32.48M | ||
| Consolidated Income | -32.48M | ||
| Earnings per Basic Share | -0.49 | ||
| Earnings per Basic Share (USD) | -0.49 | ||
| Earnings per Diluted Share | -0.49 | ||
| Earning Before Interest & Taxes (EBIT) | -32.48M | ||
| Earning Before Interest & Taxes (USD) | -32.48M | ||
| Weighted Average Shares | 66.17M | ||
| Weighted Average Shares Diluted | 66.17M | ||
| Balance Sheet | |||
| Cash and Equivalents | 135.51M | ||
| Cash and Equivalents (USD) | 135.51M | ||
| Investments | 759.65M | ||
| Investments Current | 759.65M | ||
| Current Assets | 907.34M | ||
| Property, Plant & Equipment Net | 1.64M | ||
| Total Assets | 910.22M | ||
| Current Liabilities | 14.16M | ||
| Total Liabilities | 15.07M | ||
| Accumulated Retained Earnings (Deficit) | -403.28M | ||
| Accumulated Other Comprehensive Income | -1.90M | ||
| Shareholders Equity | 895.15M | ||
| Shareholders Equity (USD) | 895.15M | ||
| Assets Non-Current | 2.88M | ||
| Liabilities Non-Current | 913.00K | ||
| Trade and Non-Trade Payables | 371.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 133.00K | ||
| Net Cash Flow from Financing | 463.42M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 3.32M | ||
| Capital Expenditure | -99.00K | ||
| Issuance (Purchase) of Equity Shares | 463.42M | ||
| Net Cash Flow from Investing | -441.57M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -441.47M | ||
| Net Cash Flow from Operations | -18.53M | ||
| Share Based Compensation | 13.92M | ||